| 57 | 1 | 22 |
| 下载次数 | 被引频次 | 阅读次数 |
目的探讨新疆地区汉族鼻咽癌患者人类白细胞抗原(HLA)A2基因型表达差异与临床特征的关联性,比较HLA-A*02阳性和阴性患者的近期疗效和远期疗效的差异。方法收集新疆医科大学附属肿瘤医院2007年1月-2014年1月接受全程IMRT放疗的初治汉族鼻咽癌患者143例的外周血标本,采用聚合酶链反应/序列特异性引物的方法提取DNA样本,进行HLA-A分型的检测,并将患者分为HLA-A*02阳性组和阴性组,比较两组患者一般临床特征和近、远期疗效。结果 143例汉族鼻咽癌患者共检出HLA-A基因型13个,HLA-A*02表达患者94例,基因频率为38.7%,构成比为42.66%(122/286)。HLA-A*02阳性组和阴性组患者的年龄、性别、病理类型、TNM分期、近期疗效差异无统计学意义。两组患者的5年总生存率(OS)、无瘤生存率(DFS)及无远处转移生存率(DMFS)分别为84.43%和76.53%(χ2=0.22,P=0.637)、82.79%和90.18%(χ2=0.09,P=0.762)、71.23%和85.90%(χ2=0.09,P=0.759),差异无统计学意义,HLA-A*02阳性组患者的5年生存率略低于阴性组患者。结论新疆汉族鼻咽癌的HLA-A基因型中,HLA-A*02仍为优势基因。HLA-A*02基因型可能不能作为估计鼻咽癌患者预后的独立因素,需要联合其他因素进行综合分析。
Abstract：Objective To analysis the relationship between the different human leukocyte antigen(HLA)A genotype and the clinical characteristics,in Han nasopharyngeal carcinoma(NPC)patients,also analyse the differences of the outcome between the HLA-A*02and other genotype.Methods Collect One hundred and forty-three Han newly diagnosed NPC patients who received the whole IMRT at the Affiliated Tumor Hospital of Xinjiang Medical University between January 2007 and 2014.Blood samples were taken before treatment,polymerase chain reaction/sequence specific primers method was used to extract DNA,tested the HLA-A genotype,and divided the patients into 2groups,HLA-A*02positive and negative,compared the differences between the clinical characteristics of these two groups,compared the difference between the recent curative effect.Results In all 143 patients,13HLA-A alleles had been tested,and a total of 94 cases were detected 122HLA-A*02gene,the gene frequency was 38.7%,the proportion was 42.66%(122/286).Age,gender,pathological pattern,TNM stages and the short-termtheropeutic effect of the patients of HLA-A*02positive and negative groups in the general clinical characteristics were seen no obvious distribution differences,with the recent curative effect is also did not see obvious difference.Five years of two groups of patients with OS,DFS,DMFS,(Kaplan-Meier method was used to analyse two groups of patients 5-year overall survival(OS),disease-free survival(DFS),no distant metastasis and survival rate(DMFS),compared two groups of survival differences).Respectively,84.43% and 76.53%(χ2=0.22,P =0.637),82.79% and 90.18%(χ2=0.09,P =0.762),71.23% and 85.90%(χ2=0.09,P =0.759),those differences were no obvious difference,statistical analysis of HLA-A*02positive patients survival rates was lower than negative one.Conclusion The Han nationality in Xinjiang HLA-A genotype of nasopharyngeal carcinoma,HLA-A*02is still the dominant genes.HLA-A*02genotype cannot estimate the prognosis of patients with nasopharyngeal carcinoma as independent factors,it need other factors comprehensive analysis.
[1]Curado MP,Edwards B,Shinhr R,et al.Cancer incidence in five continents[M].Lyon:I ARC,2007:443.
[2]Su M,Liu M,Tian DP,et al.Temporal trends of esophageal cancer during 1995-2004in Nanao Island,an extremely highrisk area in China[J].Eur J Epidemiol,2007,22(1):43-48.
[3]Guo XC,Scott K,Liu Y,et al.Genetic factors leading to chronic Epstein-Barr virus infection and nasopharyngeal carcinoma in south east china:study design,methods and feasibility[J].Hum Genomics,2006,2:365-375.
[4]Tang M,Lautenberger JA,Gao X,et al.The principal genetic determinants for nasopharyngeal carcinoma in china involve HLA class I antigen recognition groove[J].PLoS Genetics,2012,8(11):e1003103.
[5]Hei AL,Li W,Deng ZH,et al.Analysis of high-resolution HLA-A,-B,-Cw,-DRB1,and-DQB1alleles and haplotypes in 718 Chinese marrowdonors based on donor-recipient confirmatory typings[J].Int J Immunogenet,2009,36(5):275-282.
[6]Dunne C,Crowley J,Hagan R,et al.HLA-A,B,Cw,DRB1,DQB1and DPB1alleles and haplotypes in the genetically homogenous Irish population[J].Int J Immunogenet,2008,35(4-5):295-302.
[7]Vojvodi S,Ademovi-Sazdani D.HLA class I and class II polymorphism in the population of vojvodina,serbia[J].Coll Antropol,2012,36(4):1379-1384.
[8]Tyler EM,Jungbluth AA,Gnjatic S,et al.Cancer-testis antigen7expression and immune responses following allogeneic stem cell transplantation for multiple myeloma[J].Cancer Immunol Res,2014,2(6):547-558.
[9]Turcotte S,Katz SC,Shia J,et al.Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases[J].Cancer Immunol Res,2014,2(6):530-537.
[10]Yang L,Wang LJ,Shi GL,et al.Analysis of HLA-A,HLA-B and HLA-DRB1alleles in chinese patients with lung cancer[J].Genet Mol Res,2010,9(2):750-755.
[11]GoldSmith DB,West TM,Morton R.HLA associations with a nasopharyngeal carcinoma in southern chinese:a mata analysis[J].Clin Otolaryngol Allied Sci,2002,27(1):61-67.
[12]Xin Li,Ross Fasano,Ena Wang,et al.HLA associations with nsapharyngeal carcinoma[J].Curr Mol Med,2009,9(6):751-765.
[13]Provenzano M,Selleri S,Jin P,et al.Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2in normal,non tumor-bearing indibiduals[J].Cancer Immunol Immunother,2007,56(7):1047-1063.
[14]Tang M,Zeng Y,Poisson A,et al.Haplotype-dependent HLA sussceptibility to nasopharyngeal carcinoma in a Southern Chinese population[J].Genes Immunol,2010,11(4):334-342.
[15]卢亮,邓志辉,高素青,等.广东籍鼻咽癌患者与HLA等位基因相关性研究[J].国际输血及血液学杂志,2010,33(6):499-503.
[16]Yu KJ,Gao X,Chen CJ,et al.Association of human leukocyte antigens with nasopharungeal carcinoma in high-risk multiplex families in Taiwan[J].Hum Immunol,2009,70(11):910-914.
[17]Bei JX,Li Y,Jia WH,et al.A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci[J].Nat Genet,2010,42(7):596-603.
[18]Wang J,Shi M,Hsia Y,et al.Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulatedradiation in northwest china:apilot study[J].Radiat Oncol,2012,7(2):1-7.
[19]邓伟,黄天壬,陈万青,等.中国2003-2007年鼻咽癌发病与死亡分析[J].癌症,2012,32(3):189-193.
[20]Simons MJ,Day NE,Wee GB,et al.Nasopharyngeal carcinoma V:immunogenetic studies of southeast asian ethnic groups with high and low risk for the tumor[J].Cancer Res,1974,35(5):1192-1195.
[21]Middleton D,Menchaca L,Rood H,e t al.New allele frequency database[J].Tissue Antigens,2003,61(5):403-407.
[22]Wang R,Hu Y,Yindom LM,et al.Association analysis between HLA-A,-B,-C,-DRB1,and-DQB1 with nasopharyngeal carcinoma among a Han population in northwestern china[J].Hum Immunol,2014,75(3):197-202.
[23]Shi L,Yao YF,Shi L,et al.HLA allele and halotypes distribution in dai population in yunnan province,southwest china[J].Tissue Antigens,2010,75(2):159-165.
[24]Chen S,Hong W,Shao H,et al.Allelic distribution of HLA classⅠgenes in the tibetan ethnic population of china[J].Int J Immunogenet,2006,33(6):439-445.
[25]Hong W,Chen S,Shao H,et al.HLA classⅠpolymorphism in mongolian and hui ethnic groups from northern china[J].Hum Immumol,2007,68(5):439-448.
[26]Wen SH,Lai MJ,Yang KL,et al.Human leukocyte antigenA,B,and-DRB1haplotypes of cord blood units in the Tzu Chi Taiwan Cord Blood Bank[J].Hum Immumol,2008,69(7):430-436.
[27]Shen CMI,Zhu BF,Deng YJ,et al.Allele polymorphism and haplotype diversity of HLA-A,-B and-DRB1loci in sequence-based typing for Chinese Uyghur ethnic group[J].PLoS One,2010,5(11):e13458.
[28]Huh JYI,Yi DY,Eo SH,et al.HLA-A,-B and-DRB1polymorphism in Koreans defined by sequence-based typing of4128cord blood units[J].Int J Immunogenet,2013,40(6):515-523.
[29]汤敏中,李军,蔡永林,等.鼻咽癌高发区非癌人群HLA-A*02分子多态性分布[J].中国输血杂志,2013,26(4):320-323.
[30]程良红,金士正,高素青,等.中国南北方汉族人群HLA-A*02等位基因的分布差异[J].第一军医大学学报,2005,25(3):321-324.
[31]赵充,肖巍巍,韩非,等.419例鼻咽癌患者调强放疗疗效和影响[J].中华放射肿瘤学杂志,2010,19(3):191-196.
[32]韩露,林少俊,潘建基,等.305鼻咽癌调强放疗预后因素分析[J].癌症,2010,29(2):153-158.
[33]周彬,石梅,王建华,等.中国西北地区133例鼻咽癌调强放疗的预后分析[J].中华肿瘤放射性杂志,2011,20(5):374-378.
[34]Ji X,Xie C,Hu D,et al.Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma[J].PLoS One,2013,8(2):e56208.
[35]Zhang HB,Lu X,Huang SM,et al.Superficial parotid lobe–sparing delineation approach:a better method of dose optimization to protect the parotid gland in intensity-modulated radiotherapy for nasopharyngeal carcinoma[J].Curr Oncol,2013,6(20):577-584.
[36]Sun X,Su S,Chen C,et al.Long-term outcomes of intensitymodulated radiotherapy for 868patients with nasopharyngeal carcinoma:ananalysis of survival and treatment toxicities[J].Radiother Oncol,2014,110(3):398-403.
[37]易俊林,高黎,黄晓东,等.416例鼻咽癌调强放疗远期生存与影响因素分期[J].中华放射肿瘤学杂志,2012,21(3):196-200.
[38]Su SF,Han F,Zhao C,et al.Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy[J].Chin J Cancer,2011,30(8):565-573.
基本信息:
中图分类号:R739.63
引用信息:
[1]谭遥,王多明,黄莉,等.HLA-A＊02基因型与新疆汉族鼻咽癌临床特征及预后关系[J].新疆医科大学学报,2015,38(01):11-16.
基金信息:
新疆维吾尔自治区国际合作项目(20126024,201141138);; 国家自然科学基金(81160327);; 新疆维吾尔自治区青年科学基金(2011211B22)
2015-01-15
2015-01-15